WILMINGTON, DE — Incyte (Nasdaq: INCY) said Hervé Hoppenot recently resigned from its board of directors, effective immediately, formally ending a transition period that followed his long tenure as the company’s top executive.
Hoppenot, who joined Incyte in 2014, previously served as chairman and chief executive officer and had remained on the board while advising the current CEO during a planned leadership handoff. His departure marks a clean break from the company’s prior management chapter as Incyte continues to advance its next phase of growth.
Julian Baker, managing partner of Baker Bros. Advisors LP and chairman of Incyte’s board, credited Hoppenot with helping transform the company into a major force in biotechnology. Baker said Hoppenot’s leadership, vision, and guidance played a central role in building Incyte into an innovative drugmaker with a durable scientific foundation and a patient-focused mission.
Incyte is a global biopharmaceutical company focused on discovering, developing, and commercializing proprietary therapeutics for patients with serious unmet medical needs. The company has established a portfolio of first-in-class medicines and maintains a broad pipeline spanning oncology and inflammation and autoimmunity.
Headquartered in Wilmington, Delaware, Incyte operates across North America, Europe, and Asia. With Hoppenot’s exit, the board now turns its full attention to executing the company’s strategy under its current leadership team, as competition and investment scrutiny intensify across the biotech sector.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.